Synthetic Oxytocic Pharmaceuticals Will Amass Nearly US $150 Million Revenues by 2026
Though synthetic oxytocin is chemically equivalent to naturally-occurring oxytocin, their pharmaceutical functions for aiding women in labour are quite distinctive. Medical professionals from around the world will continue to recommend synthetic-based oxytocic pharmaceuticals over natural since oxytocic pharmaceuticals originating from synthetic sources can boost the momentum of decelerated labour by IV administration. More than 90% of the global market revenues for oxytocic pharmaceuticals will be harvested from the sales of oxytocic pharmaceuticals originating from synthetic sources. By the end of...
View full press release